Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 06 - 24 tags : Drug save search
$12.7 Billion Depression Drugs Global Market to 2026 - by Drug Class, Disorder Type, Drug Type, Distribution Channel and Region
Published: 2021-06-24 (Crawled : 23:00) - prnewswire.com
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: -0.26%
H: 1.13%
C: 0.78%
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.06%
H: 0.16%
C: -1.24%
depression distribution drug
Drug Safety and Risk Management Advisory Committee Roster
Published: 2021-06-24 (Crawled : 21:58) - fda.gov
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: -0.18%
H: 0.73%
C: -0.36%
risk drug
Mirati Therapeutics' Adagrasib Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Patients with Advanced Non-Small Cell Lung Cancer Harboring the KRAS G12C Mutation
Published: 2021-06-24 (Crawled : 21:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 1.24%
H: 3.82%
C: -0.12%
food lung cancer therapy cancer breakthrough therapy drug designation
Incyte Announces Outcome of FDA Oncologic Drugs Advisory Committee (ODAC) Meeting Reviewing Retifanlimab as a Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)
Published: 2021-06-24 (Crawled : 21:00) - biospace.com/
MGNX | $16.08 -0.12% -0.12% 590K
|
Health Technology
|
| O: -0.08%
H: 4.26%
C: 2.15%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: 0.33%
H: 1.31%
C: 0.84%
treatment fda oda drug cell carcinoma
Chronic Obstructive Pulmonary Disease Drugs Market To Rise in the 7MM By 2030, Analysis by DelveInsight
Published: 2021-06-24 (Crawled : 18:00) - prnewswire.com
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.29%
H: 0.8%
C: 0.17%
disease drug
Bill Newell, CEO Interviewed by Peter Hofland of The Onco’Zine Brief – “Antibody-Drug Conjugates: Coming of Age”
Published: 2021-06-24 (Crawled : 17:00) - sutrobio.com
STRO M | $3.76 -1.05% -1.06% 770K
|
Health Technology
|
| O: 1.24%
H: 3.19%
C: 2.02%
antibody drug ceo
Bill Newell, CEO Interviewed by Peter Holland of The Onco’Zine Brief – “Antibody-Drug Conjugates: Coming of Age”
Published: 2021-06-24 (Crawled : 16:00) - sutrobio.com
STRO M | $3.76 -1.05% -1.06% 770K
|
Health Technology
|
| O: 1.24%
H: 3.19%
C: 2.02%
antibody drug ceo
Spruce Biosciences Appoints Renowned Drug Developer Kirk Ways, M.D., Ph.D. to Board of Directors
Published: 2021-06-24 (Crawled : 13:00) - biospace.com/
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: 0.39%
H: 0.57%
C: 0.06%
SPRB | $0.7064 0.03% 0.03% 290K
|
Health Technology
|
| O: 0.66%
H: 3.67%
C: -0.28%
drug bioscience
Pieris Pharmaceuticals Receives Orphan Drug Designation for Cinrebafusp Alfa for the Treatment of Gastric Cancer
Published: 2021-06-24 (Crawled : 12:15) - biospace.com/
PIRS | $0.157 -0.06% -0.06% 620K
|
Health Technology
|
| O: 5.65%
H: 22.19%
C: 16.84%
treatment cancer drug designation
VectivBio Receives FDA Orphan Drug Designation for Apraglutide for Acute Graft-Versus-Host DiseasePhase 2 trial expected to begin in the first quarter of 2022
Published: 2021-06-24 (Crawled : 12:15) - biospace.com/
VECT | $16.85 0.12% 130K
|
Professional, Scientific, and T...
|
| O: 8.7%
H: 1.36%
C: -6.48%
disease fda phase 2 drug trial designation
Aquestive Therapeutics Resubmits New Drug Application for Libervant™ (diazepam) Buccal Film
Published: 2021-06-24 (Crawled : 12:00) - globenewswire.com
AQST | $4.505 14.92% 12.99% 5.8M
|
Health Technology
|
| O: 3.15%
H: 0.22%
C: -5.68%
new drug drug application
Alnylam Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Investigational Vutrisiran for the Treatment of the Polyneuropathy of Hereditary ATTR Amyloidosis
Published: 2021-06-24 (Crawled : 12:00) - biospace.com/
ALNY | News | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: 0.96%
H: 0.37%
C: -1.49%
new drug food treatment drug
VectivBio Receives FDA Orphan Drug Designation for Apraglutide for Acute Graft-Versus-Host Disease
Published: 2021-06-24 (Crawled : 12:00) - globenewswire.com
VECT | $16.85 0.12% 130K
|
Professional, Scientific, and T...
|
| O: 8.7%
H: 1.36%
C: -6.48%
disease fda drug designation
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.